

Robert B M LandewÃ©

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2671268/publications.pdf>

Version: 2024-02-01

433
papers

40,662
citations

4136

87
h-index

2894

190
g-index

436
all docs

436
docs citations

436
times ranked

20632
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.5	3,366
2	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.5	1,860
3	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 492-509.	0.5	1,688
4	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 964-975.	0.5	1,429
5	2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 978-991.	0.5	1,220
6	Dickkopf-1 is a master regulator of joint remodeling. <i>Nature Medicine</i> , 2007, 13, 156-163.	15.2	1,161
7	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 3-15.	0.5	1,114
8	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011, 63, 573-586.	6.7	864
9	Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2015, 386, 1137-1146.	6.3	722
10	American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 404-413.	0.5	657
11	Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2015, 373, 1329-1339.	13.9	629
12	Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 745-753.	2.4	625
13	Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial. <i>Arthritis and Rheumatism</i> , 2005, 52, 1756-1765.	6.7	623
14	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 700.1-712.	0.5	609
15	Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 47-53.	0.5	589
16	Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. <i>Arthritis and Rheumatism</i> , 2008, 58, 3319-3329.	6.7	539
17	Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2013, 382, 1705-1713.	6.3	518
18	2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 39-52.	0.5	506

#	ARTICLE	IF	CITATIONS
19	EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 804-814.	0.5	504
20	Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. <i>Lancet</i> , The, 2009, 374, 210-221.	6.3	497
21	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.5	484
22	Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2008, 58, 3063-3070.	6.7	461
23	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 529-535.	0.5	456
24	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 6-16.	0.5	397
25	2016 update of the EULAR recommendations for the management of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 948-959.	0.5	393
26	Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1958-1963.	0.5	383
27	2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 905-908.	0.5	365
28	Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. <i>Arthritis Research and Therapy</i> , 2009, 11, R127.	1.6	357
29	What is the most appropriate radiologic scoring method for ankylosing spondylitis?. <i>Arthritis and Rheumatism</i> , 2004, 50, 2622-2632.	6.7	335
30	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1101-1136.	0.5	277
31	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 516-528.	0.5	270
32	Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1455-1461.	0.5	263
33	Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. <i>Lancet</i> , The, 2018, 392, 2441-2451.	6.3	251
34	Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1465-1470.	0.5	244
35	Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes. <i>Cell Reports</i> , 2019, 28, 2455-2470.e5.	2.9	241
36	The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: A longitudinal analysis. <i>Arthritis and Rheumatism</i> , 2004, 50, 2082-2093.	6.7	227

#	ARTICLE	IF	CITATIONS
37	Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1623-1629.	0.5	223
38	Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. <i>Arthritis and Rheumatism</i> , 2006, 54, 1646-1652.	6.7	220
39	TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 63-69.	0.5	220
40	Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 761-772.	0.5	219
41	Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1278-1288.	0.5	218
42	Proposal for a new nomenclature of disease-modifying antirheumatic drugs: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 3-5.	0.5	212
43	Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. <i>Thrombosis and Haemostasis</i> , 2010, 104, 811-822.	1.8	207
44	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 760-770.	0.5	205
45	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 851-858.	0.5	204
46	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. <i>Lancet</i> , 2018, 392, 2378-2387.	6.3	198
47	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1113-1136.	0.5	195
48	Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212687.	0.5	193
49	Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. <i>Arthritis Research and Therapy</i> , 2016, 18, 196.	1.6	192
50	Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1016-1023.	0.5	188
51	Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1143-1151.	0.5	187
52	Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1004-1009.	0.5	179
53	Magnetic Resonance Imaging of the Sacroiliac Joints Indicating Sacroiliitis According to the Assessment of SpondyloArthritis international Society Definition in Healthy Individuals, Runners, and Women With Postpartum Back Pain. <i>Arthritis and Rheumatology</i> , 2018, 70, 1042-1048.	2.9	175
54	Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 52-59.	0.5	174

#	ARTICLE	IF	CITATIONS
55	MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1550-1558.	0.5	171
56	Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 744-759.	0.5	167
57	Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: Results from the trial of etanercept and methotrexate with radiographic and patient outcomes. <i>Arthritis and Rheumatism</i> , 2006, 54, 3119-3125.	6.7	159
58	Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1539-1540.	0.5	159
59	Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2007, 56, 1846-1853.	6.7	151
60	Smoking and overweight determine the likelihood of developing rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1654-1658.	0.5	150
61	EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 13-19.	0.5	148
62	Association of early radiographic damage with impaired physical function in rheumatoid arthritis: A ten-year, longitudinal observational study in 238 patients. <i>Arthritis and Rheumatism</i> , 2006, 54, 68-75.	6.7	137
63	The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 495-502.	0.5	136
64	Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1102-1107.	0.5	131
65	Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 518-523.	0.5	130
66	Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1823-1828.	0.5	130
67	ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1646-1653.	0.5	127
68	Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1093-1097.	0.5	126
69	MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 369-373.	0.5	126
70	Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 510-515.	0.5	123
71	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 848-858.	0.5	123
72	Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 995-1003.	0.5	122

#	ARTICLE	IF	CITATIONS
73	EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 479-481.	0.5	114
74	Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. <i>RMD Open</i> , 2019, 5, e001035.	1.8	113
75	Digital ulcers predict a worse disease course in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 681-686.	0.5	111
76	Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1123-1128.	0.5	110
77	Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. <i>RMD Open</i> , 2019, 5, e001041.	1.8	104
78	MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1486-1493.	0.5	103
79	Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1483-1487.	0.5	99
80	Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. <i>RMD Open</i> , 2017, 3, e000396.	1.8	99
81	Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 490-498.	0.5	98
82	Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 699-705.	0.5	98
83	Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. <i>Journal of Rheumatology</i> , 2007, 34, 862-70.	1.0	97
84	Presentation and analysis of data on radiographic outcome in clinical trials: Experience from the TEMPO study. <i>Arthritis and Rheumatism</i> , 2005, 52, 49-60.	6.7	96
85	Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1623-1628.	0.5	95
86	Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 414-417.	0.5	94
87	A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1430-1435.	0.5	93
88	Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis. <i>Rheumatology</i> , 2019, 58, 388-400.	0.9	93
89	EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1628-1639.	0.5	89
90	Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2004, 50, 1390-1399.	6.7	87

#	ARTICLE	IF	CITATIONS
91	EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1596-1602.	0.5	87
92	MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 2002-2005.	0.5	87
93	Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis. <i>RMD Open</i> , 2015, 1, e000153.	1.8	85
94	Patients with chronic back pain of short duration from the SPACE cohort: which MRI structural lesions in the sacroiliac joints and inflammatory and structural lesions in the spine are most specific for axial spondyloarthritis?. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1308-1314.	0.5	84
95	The Concept of Axial Spondyloarthritis: Joint Statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in Response to the US Food and Drug Administration's Comments and Concerns. <i>Arthritis and Rheumatology</i> , 2014, 66, 2649-2656.	2.9	81
96	Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. <i>Lancet, The</i> , 2018, 392, 134-144.	6.3	81
97	Disease Activity, Physical Function, and Radiographic Progression After Longterm Therapy with Adalimumab Plus Methotrexate: 5-Year Results of PREMIER. <i>Journal of Rheumatology</i> , 2010, 37, 2237-2246.	1.0	80
98	The benefits of early treatment in rheumatoid arthritis: Confounding by indication, and the issue of timing. <i>Arthritis and Rheumatism</i> , 2003, 48, 1-5.	6.7	78
99	How to Choose Core Outcome Measurement Sets for Clinical Trials: OMERACT 11 Approves Filter 2.0. <i>Journal of Rheumatology</i> , 2014, 41, 1025-1030.	1.0	78
100	Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. <i>Rheumatology</i> , 2017, 56, 1498-1509.	0.9	78
101	Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. <i>Journal of Rheumatology</i> , 2007, 34, 607-15.	1.0	78
102	Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 176-185.	0.5	76
103	Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 727-738.	0.5	76
104	Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 422-432.	0.5	75
105	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. <i>Journal of Rheumatology</i> , 2007, 34, 1740-5.	1.0	74
106	Serum 14-3-3 λ is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2104-2113.	1.0	72
107	A Fifty-two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1101-1111.	2.9	71
108	Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2016, 68, 1810-1817.	2.9	70

#	ARTICLE	IF	CITATIONS
109	Radiographic progression depicted by probability plots: Presenting data with optimal use of individual values. <i>Arthritis and Rheumatism</i> , 2004, 50, 699-706.	6.7	69
110	Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. <i>RMD Open</i> , 2017, 3, e000397.	1.8	69
111	Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1413-1420.	0.5	69
112	Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. <i>Rheumatology</i> , 2016, 55, kev340.	0.9	66
113	A stratified model for health outcomes in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1758-1764.	0.5	65
114	Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	1.5	64
115	Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. <i>RMD Open</i> , 2021, 7, e001450.	1.8	64
116	The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index. <i>Arthritis and Rheumatism</i> , 2004, 51, 154-159.	6.7	63
117	Clinical Tools to Assess and Monitor Spondyloarthritis. <i>Current Rheumatology Reports</i> , 2015, 17, 47.	2.1	63
118	Report from the OMERACT Hand Osteoarthritis Working Group: Set of Core Domains and Preliminary Set of Instruments for Use in Clinical Trials and Observational Studies. <i>Journal of Rheumatology</i> , 2015, 42, 2190-2197.	1.0	62
119	Overdiagnosis and overtreatment in rheumatology: a little caution is in order. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1394-1396.	0.5	62
120	14-3-3 β is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage. <i>Arthritis Research and Therapy</i> , 2014, 16, R99.	1.6	61
121	Repair of erosions occurs almost exclusively in damaged joints without swelling. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 851-855.	0.5	60
122	Scoring sacroiliac joints by magnetic resonance imaging. A multiple-reader reliability experiment. <i>Journal of Rheumatology</i> , 2005, 32, 2050-5.	1.0	60
123	Cartilage and Bone Biomarkers in Rheumatoid Arthritis: Prediction of 10-year Radiographic Progression. <i>Journal of Rheumatology</i> , 2009, 36, 266-272.	1.0	59
124	Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 193-201.	0.5	59
125	Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. <i>Rheumatology</i> , 2015, 54, 633-640.	0.9	57
126	Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1156-1162.	0.5	56

#	ARTICLE	IF	CITATIONS
127	Magnetic resonance imaging of inflammatory lesions in the spine in ankylosing spondylitis clinical trials: is paramagnetic contrast medium necessary?. <i>Journal of Rheumatology</i> , 2005, 32, 2056-60.	1.0	56
128	Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction?. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 709-711.	0.5	53
129	Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1671-1679.	0.5	53
130	Prevalence of Self-Reported Spondyloarthritis Features in a Cohort of Patients with Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2013, 27, 199-205.	1.8	53
131	Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1034-1042.	0.5	53
132	Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 920-928.	0.5	53
133	Endorsement of Definitions of Disease Activity States and Improvement Scores for the Ankylosing Spondylitis Disease Activity Score: Results from OMERACT 10. <i>Journal of Rheumatology</i> , 2011, 38, 1502-1506.	1.0	52
134	Magnetic resonance imaging changes of sacroiliac joints in patients with recent-onset inflammatory back pain: inter-reader reliability and prevalence of abnormalities. <i>Arthritis Research and Therapy</i> , 2006, 8, R11.	1.6	51
135	Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review. <i>Rheumatology</i> , 2015, 54, 994-1007.	0.9	51
136	Performance of the ASAS classification criteria for axial and peripheral spondyloarthritis: a systematic literature review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 886-890.	0.5	51
137	An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 124-127.	0.5	51
138	Longterm Effect of Delaying Combination Therapy with Tumor Necrosis Factor Inhibitor in Patients with Aggressive Early Rheumatoid Arthritis: 10-year Efficacy and Safety of Adalimumab from the Randomized Controlled PREMIER Trial with Open-label Extension. <i>Journal of Rheumatology</i> , 2014, 41, 5-14.	1.0	50
139	Brief Report: Calculating the Ankylosing Spondylitis Disease Activity Score If the Conventional C-reactive Protein Level Is Below the Limit of Detection or If High-sensitivity C-reactive Protein Is Used: An Analysis in the DESIR Cohort. <i>Arthritis and Rheumatology</i> , 2015, 67, 408-413.	2.9	50
140	Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. <i>Arthritis Research and Therapy</i> , 2015, 17, 14.	1.6	49
141	Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 874-878.	0.5	49
142	Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?. <i>Arthritis Research and Therapy</i> , 2013, 15, R14.	1.6	48
143	Preliminary definitions of "flare"™ in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 991-996.	0.5	48
144	Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing) Tj ETQq0 0 Q rBT /Overlock 10 T	1.5	45

#	ARTICLE	IF	CITATIONS
145	Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2094-2100.	0.5	45
146	Reference intervals of spinal mobility measures in normal individuals: the mobility study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1218-1224.	0.5	45
147	Prevalence of degenerative changes of the spine on magnetic resonance images and radiographs in patients aged 16-45 years with chronic back pain of short duration in the Spondyloarthritis Caught Early (SPACE) cohort. <i>Rheumatology</i> , 2016, 55, 56-65.	0.9	45
148	Validation of the EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, 2123-2128.	0.9	45
149	Increase in Bone Density in Patients with Spondyloarthritis During Anti-Tumor Necrosis Factor Therapy: 6-year Followup Study. <i>Journal of Rheumatology</i> , 2013, 40, 1712-1718.	1.0	44
150	Data-driven definitions for active and structural MRI lesions in the sacroiliac joint in spondyloarthritis and their predictive utility. <i>Rheumatology</i> , 2021, 60, 4778-4789.	0.9	44
151	Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review informing the 2016 update of EULAR recommendations for the management of early arthritis. <i>RMD Open</i> , 2017, 3, e000404.	1.8	43
152	Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 453-459.	0.5	43
153	The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2016, 43, 1680-1686.	1.0	42
154	The yield of a positive MRI of the spine as imaging criterion in the ASAS classification criteria for axial spondyloarthritis: results from the SPACE and DESIR cohorts. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1731-1736.	0.5	42
155	How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured?. <i>Arthritis and Rheumatism</i> , 2005, 52, 1979-1985.	6.7	41
156	How well are the ASAS/OMERACT Core Outcome Sets for Ankylosing Spondylitis implemented in randomized clinical trials? A systematic literature review. <i>Clinical Rheumatology</i> , 2014, 33, 1313-1322.	1.0	41
157	Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis. <i>RMD Open</i> , 2017, 3, e000406.	1.8	41
158	Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the SPondyloArthritis Caught Early cohort. <i>Arthritis Research and Therapy</i> , 2018, 20, 218.	1.6	41
159	What is axial spondyloarthritis? A latent class and transition analysis in the SPACE and DESIR cohorts. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 324-331.	0.5	41
160	Two different invitation approaches for consecutive rounds of a Delphi survey led to comparable final outcome. <i>Journal of Clinical Epidemiology</i> , 2021, 129, 31-39.	2.4	41
161	Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2004, 51, 1-8.	6.7	40
162	Reappraisal of OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis: The OMERACT 9 v2 Criteria. <i>Journal of Rheumatology</i> , 2009, 36, 1785-1791.	1.0	40

#	ARTICLE	IF	CITATIONS
163	Non-steroidal anti-inflammatory drugs for acute gout. The Cochrane Library, 2014, , CD010120.	1.5	40
164	Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort. RMD Open, 2017, 3, e000319.	1.8	40
165	Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis. Annals of the Rheumatic Diseases, 2018, 77, 221-227.	0.5	40
166	Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Rheumatology, 2020, 59, 1325-1334.	0.9	40
167	Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study. Annals of the Rheumatic Diseases, 2019, 78, 1033-1040.	0.5	39
168	Proposal for Levels of Evidence Schema for Validation of a Soluble Biomarker Reflecting Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis, and Recommendations for Study Design. Journal of Rheumatology, 2009, 36, 1792-1799.	1.0	38
169	Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. Rheumatology, 2012, 51, 1628-1638.	0.9	38
170	When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). RMD Open, 2016, 2, e000221.	1.8	38
171	Associations between the PTPN22 1858C->T polymorphism and radiographic joint destruction in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Annals of the Rheumatic Diseases, 2007, 66, 1604-1609.	0.5	37
172	Application of the OMERACT filter to scoring methods for magnetic resonance imaging of the sacroiliac joints and the spine. Recommendations for a research agenda at OMERACT 7. Journal of Rheumatology, 2005, 32, 2042-7.	1.0	37
173	How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis?. Annals of the Rheumatic Diseases, 2007, 66, 771-777.	0.5	36
174	Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3 Library, 2012, 1, CD008951.	1.5	36
175	Application of the 2010 ACR/EULAR classification criteria in patients with very early inflammatory arthritis: analysis of sensitivity, specificity and predictive values in the SAVE study cohort. Annals of the Rheumatic Diseases, 2013, 72, 1335-1341.	0.5	36
176	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. Annals of the Rheumatic Diseases, 2015, 74, 963-969.	0.5	36
177	Challenges in demonstrating the effectiveness of multidisciplinary treatment on quality of life, participation and health care utilisation in patients with fibromyalgia: a randomised controlled trial. Clinical Rheumatology, 2013, 32, 199-209.	1.0	35
178	Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?. RMD Open, 2015, 1, e000155-e000155.	1.8	34
179	Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study. Annals of the Rheumatic Diseases, 2018, 77, 405-411.	0.5	34
180	Comorbidities in Patients with Spondyloarthritis. Rheumatic Disease Clinics of North America, 2012, 38, 523-538.	0.8	33

#	ARTICLE	IF	CITATIONS
181	Three handy tips and a practical guide to improve your propensity score models. <i>RMD Open</i> , 2019, 5, e000953.	1.8	33
182	Nonsteroidal Antiinflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review. <i>Journal of Rheumatology</i> , 2016, 43, 607-617.	1.0	32
183	Imaging in ankylosing spondylitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006, 20, 507-519.	1.4	31
184	Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD. <i>Rheumatology</i> , 2016, 55, 1217-1224.	0.9	31
185	Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort. <i>Journal of Rheumatology</i> , 2018, 45, 506-512.	1.0	31
186	Prevalence of Comorbidities and Risk Factors for Comorbidities in Patients with Spondyloarthritis in Latin America: A Comparative Study with the General Population and Data from the ASAS-COMOSPA Study. <i>Journal of Rheumatology</i> , 2018, 45, 206-212.	1.0	31
187	EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs). <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 840-847.	0.5	31
188	No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related "physician-reported spondylitis"? <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 466-468.	0.5	31
189	Is there a preferred method for scoring activity of the spine by magnetic resonance imaging in ankylosing spondylitis?. <i>Journal of Rheumatology</i> , 2007, 34, 871-3.	1.0	31
190	Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies. <i>RMD Open</i> , 2018, 4, e000749.	1.8	30
191	Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study. <i>RMD Open</i> , 2019, 5, e000917.	1.8	30
192	Is it time to replace BASDAI with ASDAS?. <i>Nature Reviews Rheumatology</i> , 2013, 9, 388-390.	3.5	29
193	Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1811-1818.	0.5	29
194	Aspects of validity of the self-administered comorbidity questionnaire in patients with ankylosing spondylitis. <i>Rheumatology</i> , 2014, 53, 1054-1064.	0.9	29
195	14-3-3 Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 1587-1594.	1.0	28
196	Relationship between types of radiographic damage and disability in patients with rheumatoid arthritis in the EURIDISS cohort: a longitudinal study. <i>Rheumatology</i> , 2015, 54, 83-90.	0.9	28
197	Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. <i>RMD Open</i> , 2017, 3, e000430.	1.8	28
198	Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials. <i>Arthritis Research and Therapy</i> , 2016, 18, 212.	1.6	27

#	ARTICLE	IF	CITATIONS
199	Does body mass index (BMI) influence the Ankylosing Spondylitis Disease Activity Score in axial spondyloarthritis?. <i>RMD Open</i> , 2016, 2, e000283.	1.8	26
200	Hemocytometric characteristics of COVID-19 patients with and without cytokine storm syndrome on the sysmex XN-10 hematology analyzer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 783-793.	1.4	26
201	Measurement of spinal mobility in ankylosing spondylitis: comparison of occiput-to-wall and tragus-to-wall distance. <i>Journal of Rheumatology</i> , 2004, 31, 1779-84.	1.0	26
202	Accelerometer Quantification of Physical Activity and Activity Patterns in Patients with Ankylosing Spondylitis and Population Controls. <i>Journal of Rheumatology</i> , 2015, 42, 2369-2375.	1.0	25
203	Tumor Necrosis Factor Inhibitors Reduce Spinal Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: A Longitudinal Analysis From the Alberta Prospective Cohort. <i>Arthritis and Rheumatology</i> , 2021, 73, 1211-1219.	2.9	25
204	Expert agreement confirms that negative changes in hand and foot radiographs are a surrogate for repair in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2007, 9, R62.	1.6	24
205	From inhibition of radiographic progression to maintaining structural integrity: a methodological framework for radiographic progression in rheumatoid arthritis and psoriatic arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1113-1117.	0.5	24
206	Five-year follow-up of radiographic sacroiliitis: progression as well as improvement?. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1262-1263.	0.5	24
207	Individual-level and country-level socioeconomic determinants of disease outcomes in SpA: multinational, cross-sectional study (ASAS-COMOSPA). <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 486-493.	0.5	24
208	Metric Properties of the SPARCC Score of the Sacroiliac Joints " Data from Baseline, 3-month, and 12-month Followup in the SPACE Cohort. <i>Journal of Rheumatology</i> , 2015, 42, 1186-1193.	1.0	23
209	Quality indicators in rheumatoid arthritis: results from the METEOR database. <i>Rheumatology</i> , 2015, 54, 1630-1639.	0.9	23
210	A single determination of C-reactive protein does not suffice to declare a patient with a diagnosis of axial spondyloarthritis "CRP-negative"™. <i>Arthritis Research and Therapy</i> , 2018, 20, 209.	1.6	23
211	Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?. <i>Rheumatology</i> , 2019, 58, 1649-1654.	0.9	23
212	Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2015, 17, 245.	1.6	22
213	Analysis and performance of various classification criteria sets in a Colombian cohort of patients with spondyloarthritis. <i>Clinical Rheumatology</i> , 2016, 35, 1759-1767.	1.0	22
214	A psychometric analysis of outcome measures in peripheral spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1302-1307.	0.5	22
215	MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1243-1251.	0.5	22
216	Primer: challenges in randomized and observational studies. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 661-666.	3.2	21

#	ARTICLE	IF	CITATIONS
217	Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in Rheumatoid Arthritis: A Systematic Literature Search on 5 Candidate Biomarkers. <i>Journal of Rheumatology</i> , 2009, 36, 1769-1784.	1.0	21
218	The feasibility and efficacy of a multidisciplinary intervention with aftercare meetings for fibromyalgia. <i>Clinical Rheumatology</i> , 2009, 28, 923-929.	1.0	21
219	Intra articular injection with corticosteroids in patients with recent onset rheumatoid arthritis: subanalyses from the BeSt study. <i>Clinical Rheumatology</i> , 2014, 33, 263-267.	1.0	21
220	The Impact of Illness Perceptions and Coping on the Association Between Back Pain and Health Outcomes in Patients Suspected of Having Axial Spondyloarthritis: Data From the <scp>SP</scp>ondyloArthritis Caught Early Cohort. <i>Arthritis Care and Research</i> , 2018, 70, 1829-1839.	1.5	21
221	Imaging in spondylitis. <i>Current Opinion in Rheumatology</i> , 2005, 17, 413-417.	2.0	20
222	Damage and Progression on Radiographs in Individual Joints: Data from Pivotal Randomized Controlled Trials. <i>Journal of Rheumatology</i> , 2011, 38, 2018-2022.	1.0	20
223	Updating the OMERACT Filter: Core Areas as a Basis for Defining Core Outcome Sets. <i>Journal of Rheumatology</i> , 2014, 41, 994-999.	1.0	20
224	Is the Site of Back Pain Related to the Location of Magnetic Resonance Imaging Lesions in Patients With Chronic Back Pain? Results From the Spondyloarthritis Caught Early Cohort. <i>Arthritis Care and Research</i> , 2017, 69, 717-723.	1.5	20
225	Are MRI-detected erosions specific for RA? A large explorative cross-sectional study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2017-212252.	0.5	20
226	Justification for including MRI as a tool in the diagnosis of axial SpA. <i>Nature Reviews Rheumatology</i> , 2010, 6, 670-672.	3.5	19
227	OMERACT Magnetic Resonance Imaging Initiative on Structural and Inflammatory Lesions in Ankylosing Spondylitis â€” Report of a Special Interest Group at OMERACT 10 on Sacroiliac Joint and Spine Lesions. <i>Journal of Rheumatology</i> , 2011, 38, 2051-2054.	1.0	19
228	Brief Report: Erosions and Sclerosis on Radiographs Precede the Subsequent Development of Syndesmophytes at the Same Site: A Twelveâ€”Year Prospective Followup of Patients With Ankylosing Spondylitis. <i>Arthritis and Rheumatology</i> , 2014, 66, 2773-2779.	2.9	19
229	Do Smoking and Socioeconomic Factors Influence Imaging Outcomes in Axial Spondyloarthritis? Fiveâ€”Year Data From the DESIR Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 1855-1862.	2.9	19
230	Does cyclosporin A cause cancer?. <i>Nature Medicine</i> , 1999, 5, 714-714.	15.2	18
231	Ankylosing spondylitis patients with and without psoriasis do not differ in disease phenotype. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1104-1107.	0.5	18
232	Clinical and Imaging Signs of Spondyloarthritis in Firstâ€”Degree Relatives of HLAâ€”B27â€”Positive Ankylosing Spondylitis Patients: The Preâ€”Spondyloarthritis (Preâ€”SpA) Cohort Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 2444-2455.	2.9	18
233	Disease activity decrease is associated with improvement in work productivity over 1 year in early axial spondyloarthritis (SPondyloArthritis Caught Early cohort). <i>Rheumatology</i> , 2017, 56, 2222-2228.	0.9	18
234	How are enthesitis, dactylitis and nail involvement measured and reported in recent clinical trials of psoriatic arthritis? A systematic literature review. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 782-783.	0.5	18

#	ARTICLE	IF	CITATIONS
235	Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 174.	1.6	18
236	Work participation in spondyloarthritis across countries: analysis from the ASAS-COMOSPA study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1303-1310.	0.5	18
237	Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1022-1030.	0.5	18
238	Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. <i>RMD Open</i> , 2021, 7, e001600.	1.8	18
239	Instrument selection for the ASAS core outcome set for axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 763-772.	0.5	18
240	Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 133.	1.6	17
241	Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts. <i>RMD Open</i> , 2015, 1, e000128.	1.8	17
242	Short-term changes on MRI predict long-term changes on radiography in rheumatoid arthritis: an analysis by an OMERACT Task Force of pooled data from four randomised controlled trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 992-997.	0.5	17
243	An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity. <i>Arthritis and Rheumatology</i> , 2018, 70, 1557-1564.	2.9	17
244	Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment. <i>PLoS ONE</i> , 2018, 13, e0192425.	1.1	17
245	Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohort. <i>PLoS ONE</i> , 2020, 15, e0230268.	1.1	17
246	Use of multidimensional composite scores in rheumatology: parsimony versus subtlety. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 280-285.	0.5	17
247	Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome. <i>European Journal of Case Reports in Internal Medicine</i> , 2020, 7, 1.	0.2	17
248	Early aggressive therapy in rheumatoid arthritis: a 'window of opportunity'?. <i>Nature Clinical Practice Rheumatology</i> , 2005, 1, 2-3.	3.2	16
249	Joint space narrowing, cartilage and physical function: are we deceived by measurements and distributions?. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 717-718.	0.5	16
250	Hierarchy of Impairment of Spinal Mobility Measures in Ankylosing Spondylitis: Twelve-Year Data. <i>Arthritis Care and Research</i> , 2015, 67, 1571-1577.	1.5	16
251	Intra-articular etanercept treatment in inflammatory arthritis: A randomized double-blind placebo-controlled proof of mechanism clinical trial validating TNF as a potential therapeutic target for local treatment. <i>Joint Bone Spine</i> , 2015, 82, 338-344.	0.8	16
252	The performance of different classification criteria sets for spondyloarthritis in the worldwide ASAS-COMOSPA study. <i>Arthritis Research and Therapy</i> , 2017, 19, 96.	1.6	16

#	ARTICLE	IF	CITATIONS
253	Is the current ASAS expert definition of a positive family history useful in identifying axial spondyloarthritis? Results from the SPACE and DESIR cohorts. <i>Arthritis Research and Therapy</i> , 2017, 19, 118.	1.6	16
254	Lessons to be learned from serum biomarkers in psoriasis and IBD – the potential role in SpA. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 333-344.	1.3	16
255	Should radiographic progression still be used as outcome in RA?. <i>Clinical Immunology</i> , 2018, 186, 79-81.	1.4	16
256	Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. <i>RMD Open</i> , 2018, 4, e000766.	1.8	16
257	Do ethnicity, degree of family relationship, and the spondyloarthritis subtype in affected relatives influence the association between a positive family history for spondyloarthritis and HLA-B27 carriership? Results from the worldwide ASAS cohort. <i>Arthritis Research and Therapy</i> , 2018, 20, 166.	1.6	16
258	Sex-associated Treatment Differences and Their Outcomes in Rheumatoid Arthritis: Results from the METEOR Register. <i>Journal of Rheumatology</i> , 2018, 45, 1361-1366.	1.0	16
259	Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort. <i>Journal of Rheumatology</i> , 2020, 47, 809-819.	1.0	16
260	Biological DMARDs and disease modification in axial spondyloarthritis: a review through the lens of causal inference. <i>RMD Open</i> , 2021, 7, e001654.	1.8	16
261	Assessment of global disease activity in RA patients monitored in the METEOR database: the patient's versus the rheumatologist's opinion. <i>Clinical Rheumatology</i> , 2014, 33, 461-466.	1.0	15
262	Fluctuations in patient reported disease activity, pain and global being in patients with ankylosing spondylitis. <i>Rheumatology</i> , 2016, 55, 2014-2022.	0.9	15
263	Social Role Participation in Patients With Ankylosing Spondylitis: A Cross-sectional Comparison With Population Controls. <i>Arthritis Care and Research</i> , 2016, 68, 1899-1905.	1.5	15
264	Social Role Participation and Satisfaction With Life: A Study Among Patients With Ankylosing Spondylitis and Population Controls. <i>Arthritis Care and Research</i> , 2018, 70, 600-607.	1.5	15
265	Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life. <i>RMD Open</i> , 2018, 4, e000755.	1.8	15
266	LB0001 – EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH1 PRIMARY OUTCOME RESULTS. , 2019, , .		15
267	Is Treatment in Patients With Suspected Nonradiographic Axial Spondyloarthritis Effective? Six-Month Results of a Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 806-815.	2.9	15
268	Are syndesmophytes most prevalent in the lumbar or in the cervical spine in patients with ankylosing spondylitis and do they develop in a specific direction?. <i>Rheumatology</i> , 2012, 51, 1432-1439.	0.9	14
269	Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice. <i>RMD Open</i> , 2019, 5, e001050.	1.8	14
270	How to treat patients with rheumatoid arthritis when methotrexate has failed? The use of a multiple propensity score to adjust for confounding by indication in observational studies. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 25-30.	0.5	14

#	ARTICLE	IF	CITATIONS
271	Central reader evaluation of MRI scans of the sacroiliac joints from the ASAS classification cohort: discrepancies with local readers and impact on the performance of the ASAS criteria. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 935-942.	0.5	14
272	Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 937-943.	0.5	14
273	Multiple Computer-based Methods of Measuring Joint Space Width Can Discriminate Between Treatment Arms in the COBRA Trial – Update of an Ongoing OMERACT Project. <i>Journal of Rheumatology</i> , 2009, 36, 1825-1828.	1.0	13
274	Diagnostic and Prognostic Value of Synovial Biopsy in Adult Undifferentiated Peripheral Inflammatory Arthritis: A Systematic Review. <i>Journal of rheumatology Supplement, The</i> , 2011, 87, 45-47.	2.2	13
275	Comment on: –Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial – by Qian-wen<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e62-e62.	0.5	13
276	Analysis of Integrated Radiographic Data From Two Long-Term, Open-Label Extension Studies of Adalimumab for the Treatment of Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2015, 67, 180-186.	1.5	13
277	Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity. <i>Rheumatology</i> , 2019, 58, 1025-1033.	0.9	13
278	Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE. <i>Rheumatology and Therapy</i> , 2020, 7, 581-599.	1.1	13
279	Nonsteroidal Anti-inflammatory Drugs for Treatment of Acute Gout. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2276.	3.8	12
280	Comparison of Tests for Lumbar Flexion and Hip Function in Patients With and Without Axial Spondyloarthritis. <i>Arthritis Care and Research</i> , 2015, 67, 538-545.	1.5	12
281	–Big Data–in Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2018, 44, 307-315.	0.8	12
282	Imaging of the sacroiliac joints is important for diagnosing early axial spondyloarthritis but not all-decisive. <i>Rheumatology</i> , 2018, 57, 1173-1179.	0.9	12
283	Percentage of progressors in imaging: can we ignore regressors?. <i>RMD Open</i> , 2019, 5, e000848.	1.8	12
284	The earlier, the better or the worse? Towards accurate management of patients with arthralgia at risk for RA. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 312-315.	0.5	12
285	Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis: a 2-year study comparing treatment with etanercept in EMBARK to a contemporary control cohort in DESIR. <i>Arthritis Research and Therapy</i> , 2021, 23, 43.	1.6	12
286	EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 780-785.	0.5	12
287	RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 713-720.	1.3	11
288	Algorithm for Identification of Undifferentiated Peripheral Inflammatory Arthritis: A Multinational Collaboration Through the 3e Initiative. <i>Journal of rheumatology Supplement, The</i> , 2011, 87, 54-58.	2.2	11

#	ARTICLE	IF	CITATIONS
289	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1755-1760.	0.5	11
290	Quality in rheumatoid arthritis care. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 664-679.	1.4	11
291	Impact of replacing radiographic sacroiliitis by magnetic resonance imaging structural lesions on the classification of patients with axial spondyloarthritis. <i>Rheumatology</i> , 2018, 57, 1186-1193.	0.9	11
292	Frequency of Impaired Spinal Mobility in Patients with Chronic Back Pain Compared to Patients with Early Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , 2018, 45, 1643-1650.	1.0	11
293	Is active sacroiliitis on MRI associated with radiographic damage in axial spondyloarthritis? Real-life data from the ASAS and DESIR cohorts. <i>Rheumatology</i> , 2019, 58, 798-802.	0.9	11
294	Principles of assessment from a clinical perspective. <i>Best Practice and Research in Clinical Rheumatology</i> , 2003, 17, 365-379.	1.4	10
295	Magnetic Resonance Imaging in the Diagnosis of Ankylosing Spondylitis: Be Aware of Gold Standards and Circularity. <i>Journal of Rheumatology</i> , 2010, 37, 477-478.	1.0	10
296	Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1655-1659.	0.5	10
297	How Do Gastrointestinal or Liver Comorbidities Influence the Choice of Pain Treatment in Inflammatory Arthritis? A Cochrane Systematic Review. <i>Journal of rheumatology Supplement</i> , The, 2012, 90, 74-80.	2.2	10
298	Editorial: Methotrexate saves lives: A pearl of observational research. <i>Arthritis and Rheumatism</i> , 2013, 65, 307-309.	6.7	10
299	In Early Axial Spondyloarthritis, Increasing Disease Activity Is Associated with Worsening of Health-related Quality of Life over Time. <i>Journal of Rheumatology</i> , 2018, 45, 779-784.	1.0	10
300	Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patients' Burden of Disease. <i>Arthritis Care and Research</i> , 2018, 70, 516-524.	1.5	10
301	Disease activity is associated with spinal radiographic progression in axial spondyloarthritis independently of exposure to tumour necrosis factor inhibitors. <i>Rheumatology</i> , 2021, 60, 461-462.	0.9	10
302	Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial. <i>Rheumatology</i> , 2021, , .	0.9	10
303	Do extra-articular manifestations influence outcome in ankylosing spondylitis? 12-year results from OASIS. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 214-21.	0.4	10
304	The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28. <i>Arthritis Research and Therapy</i> , 2006, 8, 107.	1.6	9
305	Evaluating patient reported outcomes in routine practice of patients with rheumatoid arthritis treated with biological disease modifying anti rheumatic drugs (b-DMARDs). <i>SpringerPlus</i> , 2015, 4, 462.	1.2	9
306	Validation and reliability of translation of the ASAS Health Index in a Colombian Spanish-speaking population with spondyloarthritis. <i>Clinical Rheumatology</i> , 2018, 37, 3063-3068.	1.0	9

#	ARTICLE	IF	CITATIONS
307	Do Illness Perceptions and Coping Strategies Change Over Time in Patients Recently Diagnosed With Axial Spondyloarthritis?. <i>Journal of Rheumatology</i> , 2020, 47, 1752-1759.	1.0	9
308	Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable. <i>Rheumatology</i> , 2021, 60, 638-648.	0.9	9
309	Determinants of the patient global assessment of well-being in early axial spondyloarthritis: 5-year longitudinal data from the DESIR cohort. <i>Rheumatology</i> , 2021, 60, 316-321.	0.9	9
310	COVID-19-induced hyperinflammation, immunosuppression, recovery and survival: how causal inference may help draw robust conclusions. <i>RMD Open</i> , 2021, 7, e001638.	1.8	9
311	Progression from subclinical inflammation to overt SpA in first degree relatives of SpA patients is associated with HLA-B*27: the Pre-SpA cohort. <i>Arthritis Care and Research</i> , 2021, , .	1.5	9
312	Role of vertebral corner inflammation and fat deposition on MRI on syndesmophyte development detected on whole spine low-dose CT scan in radiographic axial spondyloarthritis. <i>RMD Open</i> , 2022, 8, e002250.	1.8	9
313	Adenosine 5'-triphosphate infusions reduced disease activity and inflammation in a patient with active rheumatoid arthritis. <i>Rheumatology</i> , 2010, 49, 2223-2225.	0.9	8
314	Bone Marrow Edema on Magnetic Resonance Imaging (MRI) of the Sacroiliac Joints Is Associated with Development of Fatty Lesions on MRI over a 1-year Interval in Patients with Early Inflammatory Low Back Pain: A 2-year Followup Study. <i>Journal of Rheumatology</i> , 2014, 41, 1088-1094.	1.0	8
315	Linear extrapolation of missing radiographic change scores in clinical trials does not spuriously overestimate group radiographic changes in rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 1295-1300.	0.9	8
316	In patients with axial spondyloarthritis, inflammation on MRI of the spine is longitudinally related to disease activity only in men: 2 years of the axial spondyloarthritis DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 470-472.	0.5	8
317	Depressive mood and low social support are not associated with arthritis development in patients with seropositive arthralgia, although they predict increased musculoskeletal symptoms. <i>RMD Open</i> , 2018, 4, e000653.	1.8	8
318	Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT). <i>Arthritis Research and Therapy</i> , 2020, 22, 225.	1.6	8
319	A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2021, 48, 1259-1267.	1.0	8
320	Definition of Treatment Targets in Rheumatoid Arthritis: Is It Time for Reappraisal?. <i>Journal of Rheumatology</i> , 2021, 48, 1763-1766.	1.0	8
321	Association of the different types of radiographic damage with physical function in patients with rheumatoid arthritis: analysis of the RAPID trials. <i>RMD Open</i> , 2016, 2, e000219.	1.8	8
322	A Randomized Trial of Tai Chi for Fibromyalgia. <i>New England Journal of Medicine</i> , 2010, 363, 2265-2267.	13.9	7
323	Diagnostic and Predictive Value of Acute-phase Reactants in Adult Undifferentiated Peripheral Inflammatory Arthritis: A Systematic Review. <i>Journal of rheumatology Supplement</i> , The, 2011, 87, 15-19.	2.2	7
324	Effects of Cardiovascular Comorbidities on Work Participation in Rheumatic Diseases: A Prospective Cohort Study Among Working Individuals. <i>Arthritis Care and Research</i> , 2014, 66, 157-163.	1.5	7

#	ARTICLE	IF	CITATIONS
325	Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 349-354.	0.5	7
326	Conventional DMARDs in axial spondyloarthritis: wishfulâ€“rather than rationalâ€“thinking!. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 951-953.	0.5	7
327	Social Role Participation Questionnaire for patients with ankylosing spondylitis: translation into Dutch, reliability and construct validity. <i>RMD Open</i> , 2016, 2, e000177.	1.8	7
328	Resource utilisation and direct costs in patients with recently diagnosed fibromyalgia who are offered one of three different interventions in a randomised pragmatic trial. <i>Clinical Rheumatology</i> , 2016, 35, 1307-1315.	1.0	7
329	Is radiographic progression in radiographic axial spondyloarthritis related to matrix metalloproteinase degradation of extracellular matrix?. <i>RMD Open</i> , 2018, 4, e000648.	1.8	7
330	Radiographic sacroiliitis progression in axial spondyloarthritis: central reading of 5-year follow-up data from the Assessment of SpondyloArthritis international Society cohort. <i>Rheumatology</i> , 2021, 60, 2478-2480.	0.9	7
331	Spondyloarthritis features forecasting the presence of HLA-B27 or sacroiliitis on magnetic resonance imaging in patients with suspected axial spondyloarthritis: results from a cross-sectional study in the ESPeranza Cohort. <i>Arthritis Research and Therapy</i> , 2015, 17, 265.	1.6	6
332	What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?. <i>RMD Open</i> , 2017, 3, e000327.	1.8	6
333	Why CAPS criteria are not diagnostic criteria?. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e7-e7.	0.5	6
334	The influence of discrepant imaging judgements on the classification of axial spondyloarthritis is limited: a replication in the SpondyloArthritis Caught Early (SPACE) cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e1-e1.	0.5	6
335	Response to: 'Dual target strategy: a proposal to mitigate the risk of overtreatment and enhance patient satisfaction in rheumatoid arthritis' by Ferreira et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e110-e110.	0.5	6
336	Inhibition of spinal bone formation in AS: 10 years after comparing adalimumab to OASIS. <i>Arthritis Research and Therapy</i> , 2019, 21, 225.	1.6	6
337	Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study' by Calvo-Aranda et al'. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e35-e35.	0.5	6
338	Sick leave in early axial spondyloarthritis: the role of clinical and socioeconomic factors. Five-year data from the DESIR cohort. <i>RMD Open</i> , 2021, 7, e001685.	1.8	6
339	Tools for monitoring spondyloarthritis in clinical practice. <i>Nature Reviews Rheumatology</i> , 2009, 5, 608-615.	3.5	5
340	Editorial: How Publication Bias May Harm Treatment Guidelines. <i>Arthritis and Rheumatology</i> , 2014, 66, 2661-2663.	2.9	5
341	How to deal with missing items in BASDAI and BASFI. <i>Rheumatology</i> , 2014, 53, 374-376.	0.9	5
342	Predictors for health improvement in patients with fibromyalgia: a 2-year follow-up study. <i>Clinical Rheumatology</i> , 2015, 34, 133-141.	1.0	5

#	ARTICLE	IF	CITATIONS
343	New concepts of clinical trials in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 316-322.	2.0	5
344	Evaluating quality of care in rheumatoid arthritis: the patient perspective. <i>RMD Open</i> , 2017, 3, e000411.	1.8	5
345	Is there a relationship between spondyloarthritis and periodontitis? A case-control study. <i>RMD Open</i> , 2017, 3, e000547.	1.8	5
346	Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time. <i>RMD Open</i> , 2019, 5, e000836.	1.8	5
347	LB0003...EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS NAIVE TO METHOTREXATE THERAPY: FINCH3 PRIMARY OUTCOME RESULTS. , 2019, , .		5
348	Which imaging outcomes for axSpA are most sensitive to change? A 5-year analysis of The DESIR Cohort. <i>Arthritis Care and Research</i> , 2020, , .	1.5	5
349	Integrated longitudinal analysis does not compromise precision and reduces bias in the study of imaging outcomes: A comparative 5-year analysis in the DESIR cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1394-1399.	1.6	5
350	Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study. <i>RMD Open</i> , 2021, 7, e001728.	1.8	5
351	OMERACT 10 Sharp Symposium: Important Findings in Examination of Imaging Methods for Measurement of Joint Damage in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 2009-2013.	1.0	4
352	Response to: "2016 update of the EULAR recommendations for the management of rheumatoid arthritis: no utopia for patients in low/middle-income countries?" by Misra et al. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e48-e48.	0.5	4
353	Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy. <i>Rheumatology</i> , 2017, 56, 1721-1728.	0.9	4
354	Further Treatment Intensification in Undifferentiated and Rheumatoid Arthritis Patients Already in Low Disease Activity has Limited Benefit towards Physical Functioning. <i>Arthritis Research and Therapy</i> , 2017, 19, 220.	1.6	4
355	Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment. <i>BMC Rheumatology</i> , 2019, 3, 3.	0.6	4
356	Comparative construct validity of three presenteeism instruments in workers with musculoskeletal complaints: a prospective cohort study. <i>RMD Open</i> , 2020, 6, e001281.	1.8	4
357	The role of biochemical markers of joint tissue remodelling to predict progression and treatment efficacy in inflammatory rheumatic diseases. <i>Rheumatology</i> , 2020, 59, 1207-1217.	0.9	4
358	Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies. <i>Rheumatology</i> , 2021, 60, 1708-1716.	0.9	4
359	Three-month and six-month outcomes of patients with COVID-19 associated hyperinflammation treated with short-term immunosuppressive therapy: follow-up of the CHIC study. <i>RMD Open</i> , 2021, 7, e001906.	1.8	4
360	Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. <i>RMD Open</i> , 2021, 7, e001818.	1.8	4

#	ARTICLE	IF	CITATIONS
361	American College of Rheumatology recommendations for the treatment of RA: an issue of choices. <i>Nature Clinical Practice Rheumatology</i> , 2009, 5, 8-9.	3.2	3
362	Efficacy assessed in follow-ups of clinical trials: methodological conundrum. <i>Arthritis Research and Therapy</i> , 2010, 12, 132.	1.6	3
363	Are conventional radiographs still of value?. <i>Current Opinion in Rheumatology</i> , 2016, 28, 310-315.	2.0	3
364	Alternative diagnoses in patients with chronic back pain not diagnosed with axial spondyloarthritis: data from the SPACE cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212175.	0.5	3
365	Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 258.	1.6	3
366	Are globals for health, well-being and quality of life interchangeable? A mixed methods study in ankylosing spondylitis patients and controls. <i>Rheumatology</i> , 2018, 57, 1555-1562.	0.9	3
367	Response to: 'Early identification of rheumatoid arthritis; the risk of overtreatment in perspective' by LandewÄ©. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e108-e108.	0.5	3
368	The Development and Evaluation of Personalized Training in Shared Decision-making Skills for Rheumatologists. <i>Journal of Rheumatology</i> , 2020, 47, 290-297.	1.0	3
369	Association of 17 Definitions of Remission with Functional Status in a Large Clinical Practice Cohort of Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2020, 47, 20-27.	1.0	3
370	Validation of the self-administered comorbidity questionnaire adjusted for spondyloarthritis: results from the ASAS-COMOSPA study. <i>Rheumatology</i> , 2020, 59, 1632-1639.	0.9	3
371	Which disease activity outcome measure discriminates best in axial spondyloarthritis? A systematic literature review and meta-analysis. <i>Rheumatology</i> , 2020, 59, 3990-3992.	0.9	3
372	Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RA. <i>Journal of Rheumatology</i> , 2020, 47, 796-808.	1.0	3
373	COVID-19 and how evidence of a new disease evolves. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 401-402.	0.5	3
374	Domains to Be Considered for the Core Outcome Set of Axial Spondyloarthritis: Results From a 3-round Delphi Survey. <i>Journal of Rheumatology</i> , 2021, 48, 1810-1814.	1.0	3
375	Defining an optimal referral strategy for patients with a suspicion of axial spondyloarthritis: what is really important? Response to: 'Evaluating the ASAS recommendations for early referral of axial spondyloarthritis in patients with chronic low back pain; is one parameter present sufficient for primary care practice?' by van Hove et al. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1-1.	0.5	3
376	Response to: Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related physician-reported spondylitis' by Siebert and Marzo-Ortega. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e186-e186.	0.5	3
377	Associations between syndesmophytes and facet joint ankylosis in radiographic axial spondyloarthritis patients on low-dose CT over 2 years. <i>Rheumatology</i> , 2022, 61, 4722-4730.	0.9	3
378	Dramatic Repair of Joint Damage in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 969-970.	1.0	2

#	ARTICLE	IF	CITATIONS
379	Rate of adjudication of radiological progression in rheumatoid arthritis randomized controlled trials depending on preset limits of agreement: a pooled analysis from 15 randomized trials. <i>Rheumatology</i> , 2013, 52, 1404-1407.	0.9	2
380	85.â€ŒFinal 5-Year Safety and Efficacy Results of a Phase 3, Randomized, Placebo-Controlled Trial of Golimumab in Patients with Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy. <i>Rheumatology</i> , 2014, 53, i87-i88.	0.9	2
381	Neutral lateral fingertip-to-floor distance can be derived from height. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1748-1749.	0.5	2
382	Comparison of characteristics of international and national databases for rheumatoid arthritis: a systematic literature review. <i>Scandinavian Journal of Rheumatology</i> , 2014, 43, 349-355.	0.6	2
383	Cardiovascular Morbidity and Mortality Among Working Individuals With Rheumatic Disease. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 359-363.	0.5	2
384	Erosions in the foot at baseline are predictive of orthopaedic shoe use after 10Âyears of treat to target therapy in patients with recent onset rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 2101-2107.	1.0	2
385	DAS steered therapy in clinical practice; cross-sectional results from the METEOR database. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 33.	0.8	2
386	Do we need new trial designs in spondyloarthritis?. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, S8-S10.	1.6	2
387	Response to: â€ŒHigh dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumabâ€™ by Conticini<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e203-e203.	0.5	2
388	Response to: â€™Correspondence on â€ŒHistorically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC studyâ€™â€™ by Charles. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e109-e109.	0.5	2
389	The unsustainable bubble of disease-modifying antirheumatic drugs in rheumatology. <i>Lancet Rheumatology</i> , The, 2021, 3, e306-e312.	2.2	2
390	Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1362-1363.	0.5	2
391	Factors associated with the decision of the rheumatologist to order sacroiliac joints magnetic resonance imaging (SI-MRI) or HLA-B27 testing in the diagnostic work-up of patients with spondyloarthritis in clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 122-128.	0.4	2
392	Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study. <i>RMD Open</i> , 2022, 8, e002138.	1.8	2
393	Response to: Correspondence on â€ŒNo efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post hoc analyses of psoriatic arthritis-related â€Œphysician-reported spondylitisâ€™â€™ by Braun and LandewÄ©. <i>Annals of the Rheumatic Diseases</i> , 2022, , annrheumdis-2022-222359.	0.5	2
394	On publication policy, combination therapy, and the European League Against Rheumatism recommendations for the management of rheumatoid arthritis: Comment on the article by Graudal et al. <i>Arthritis and Rheumatism</i> , 2011, 63, 3182-3185.	6.7	1
395	New analysis tools for observational studies. <i>Zeitschrift Fur Rheumatologie</i> , 2015, 74, 113-118.	0.5	1
396	Response to: â€ŒThe GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studiesâ€™ by Tillet <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e24-e24.	0.5	1

#	ARTICLE	IF	CITATIONS
397	Systematic review of rheumatoid arthritis clinical studies: Suboptimal statistical analysis of radiological data. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 218-221.	1.6	1
398	FRI0408â€¦EARLIER TREATMENT OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH CERTOLIZUMAB PEGOL RESULTS IN IMPROVED CLINICAL OUTCOMES. , 2019, , .		1
399	LB0006â€¦SUBCUTANEOUS SECUKINUMAB 300MG AND 150MG PROVIDES SUSTAINED INHIBITION OF RADIOGRAPHIC PROGRESSION IN PSORIATIC ARTHRITIS OVER 2 YEARS: RESULTS FROM THE PHASE 3 FUTURE-5 TRIAL. , 2019, , .		1
400	Response to: â€˜Catching the falling star: points to consider when using propensity scoresâ€™™ by Ouyang <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e27-e27.	0.5	1
401	Response to â€˜Neither earlier not late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort studyâ€™™ by Moiseev et al. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2020-219295.	0.5	1
402	Response to: â€˜Correspondence on â€˜Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC studyâ€™™â€™™ by De Santis<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e112-e112.	0.5	1
403	Ultrasound-guided lymph node biopsy sampling to study the immunopathogenesis of rheumatoid arthritis: a well-tolerated valuable research tool. <i>Arthritis Research and Therapy</i> , 2022, 24, 36.	1.6	1
404	Searching for potential biomarkers that can be used as biomarkers for diagnosing ankylosing spondylitis. <i>Biomarkers in Medicine</i> , 2008, 2, 23-30.	0.6	0
405	SP0064â€¦Spondyloarthritis: What is new for primary care?. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 16.2-16.	0.5	0
406	Reply. <i>Arthritis and Rheumatology</i> , 2015, 67, 856-857.	2.9	0
407	THU0069â€¦Influence of The Difference between Patient and Physician Global Assessment on Disease Activity Status in High and Lower Income Countries: Data from The Meteor Database. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 203.2-204.	0.5	0
408	O49â€¦Synovial Lymphocytic Aggregates Associate with Highly Active RA and Predict Erosive Disease Progression at 12 Months: Results from the Pathobiology of Early Arthritis Cohort. <i>Rheumatology</i> , 2016, , .	0.9	0
409	Injection intra-articulaire dâ€™tanercept dans le traitement local des rhumatismes inflammatoires: Â©tude pilote contrÃ©e avec Â©tude de mÃ©canisme. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2016, 83, 274-280.	0.0	0
410	Reply. <i>Arthritis and Rheumatology</i> , 2017, 69, 1124-1125.	2.9	0
411	Response to: â€˜The time has come to revisit alternative interpretations of data underlying the EULAR management recommendations for rheumatoid arthritisâ€™™ by PiriÃ© <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e50-e50.	0.5	0
412	Appropriate use of the EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e15-e15.	0.5	0
413	FRI0397â€¦EFFICACY AND SAFETY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL: RESULTS FROM THE 48-WEEK RUN-IN PART OF C-OPTIMISE. , 2019, , .		0
414	OP0037â€¦ASSOCIATION BETWEEN BONE MARROW EDEMA AND STRUCTURAL PROGRESSION IN THE SAME QUADRANT IN AXIAL SPONDYLOARTHRITIS â€˜ 5-YEAR DATA FROM THE DESIR COHORT. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
415	SAT0349â€¦...HIGHER DISEASE ACTIVITY IS ASSOCIATED WITH MORE SPINAL RADIOGRAPHIC PROGRESSION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS. , 2019, , .		0
416	OP0034â€¦...DO SMOKING AND SOCIO-ECONOMIC FACTORS INDEPENDENTLY INFLUENCE IMAGING OUTCOMES IN AXIAL SPONDYLOARTHRITIS? FIVE-YEAR DATA FROM THE DESIR COHORT. , 2019, , .		0
417	AB0711â€¦...IXEKIZUMAB IMPROVES SIGNS AND SYMPTOMS AND SPINAL INFLAMMATION OF ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THROUGH ONE YEAR OF TREATMENT IN BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUG-NAÏVE PATIENTS. , 2019, , .		0
418	FRI0410â€¦...TNF INHIBITORS REDUCE SPINAL RADIOGRAPHIC PROGRESSION IN AXIAL SPONDYLOARTHRITIS (PARTIALLY) BY DECREASING DISEASE ACTIVITY. , 2019, , .		0
419	OP0033â€¦...WHAT IS AXIAL SPONDYLOARTHRITIS? A LATENT CLASS AND TRANSITION ANALYSIS IN THE SPACE AND DESIR COHORTS. , 2019, , .		0
420	THU0358â€¦...DEVELOPMENT OF A SET OF ASAS QUALITY STANDARDS FOR ADULTS WITH AXIAL SPONDYLOARTHRITIS. , 2019, , .		0
421	THU0360â€¦...INCREASING IMPACT ON STRUCTURAL DAMAGE WITH INCREASING CUMULATIVE INFLAMMATION AT THE SJJOINT QUADRANT LEVEL IN AXIAL SPONDYLOARTHRITIS â€” 5-YEAR DATA FROM THE DESIR COHORT. , 2019, , .		0
422	SAT0309â€¦...CLINICAL, IMAGING AND BIOLOGIC FEATURES OF SPONDYLOARTHRITIS IN AN AT-RISK POPULATION: DATA FROM THE PRE-SPA COHORT. , 2019, , .		0
423	THU0363â€¦...DO ILLNESS PERCEPTIONS AND COPING CHANGE OVER TIME IN PATIENTS RECENTLY DIAGNOSED WITH AXIAL SPONDYLOARTHRITIS? A 2-YEAR FOLLOW-UP STUDY IN THE SPACE COHORT. , 2019, , .		0
424	Response to: â€”Metering the METEOR in methotrexate failure: is propensity score a falling star?â€™™ by Ahmed <i>et al</i>. Annals of the Rheumatic Diseases, 2019, 78, e132-e132.	0.5	0
425	Response to: â€”Should patients starting biologics be screened for COVID-19?â€™™ by Cardenas-de la Garza <i>et al</i>. Annals of the Rheumatic Diseases, 2022, 81, e151-e151.	0.5	0
426	P62â€¦fAssessing the effect of increased body mass on response to DMARD treatment in rheumatoid arthritis: results from the METEOR database. Rheumatology, 2020, 59, .	0.9	0
427	Response to: â€”Reactive arthritis, a missing link: comment on the recent article from Sepriano <i>et al</i>â€™™ by Zeidler and Hudson. Annals of the Rheumatic Diseases, 2022, 81, e41-e41.	0.5	0
428	P133â€¦fFilgotinib in patients with RA with inadequate response to methotrexate: FINCH 1 52-week efficacy and patient reported outcomes data. Rheumatology, 2021, 60, .	0.9	0
429	Response to: â€”Correspondence on â€”Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC studyâ€™™â€™™ by Kaklamanos <i>et al</i>. Annals of the Rheumatic Diseases, 2023, 82, e135-e135.	0.5	0
430	Reply. Arthritis and Rheumatology, 2021, 73, 2352-2353.	2.9	0
431	Response to: â€”Correspondence on â€”Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC studyâ€™™â€™™ by Klopfenstein et al. Annals of the Rheumatic Diseases, 2021, , annrhumdis-2021-220787.	0.5	0
432	Biologics and switch in rheumatoid arthritis throughout time - are we being more aggressive?. Acta ReumatolÃ³gica Portuguesa, 2011, 36, 234-42.	0.2	0

#	ARTICLE	IF	CITATIONS
433	Does a short course of etanercept influence disease progression and radiographic changes in patients suspected of non-radiographic axial spondyloarthritis? Three -years follow- up of a placebo-controlled trial. Scandinavian Journal of Rheumatology, 2022, , 1-5.	0.6	0